Gout is a chronic inflammatory condition characterized by the deposition of monosodium urate crystals within the organs.[@bib1]^,^[@bib2] Hyperuricemia is known to increase the risk of gout attacks[@bib3] and incidence of uric acid kidney stones.[@bib4] Consequently, therapeutic lowering of the serum uric acid level is the focus of the management of gout.[@bib5] Traditionally, this has been achieved either by reducing the production of uric acid with the use of xanthine oxidase inhibitors and/or enhancement of uric acid excretion with a uricosuric agent.[@bib6] Febuxostat is a selective non--purine based xanthine oxidase inhibitor that limits the production of uric acid.[@bib7]^,^[@bib8]

Recent studies have raised safety concerns regarding the use of febuxostat in the management of hyperuricemia. The Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial reported a higher risk of cardiovascular mortality with the use febuxostat vs control[@bib9] that led to a boxed warning by the US Food and Drug Administration in 2019.[@bib10] However, since the mortality hazard was shown in a single randomized controlled trial (RCT), assessment of the drug's safety profile in larger population settings is warranted. A recent meta-analysis[@bib11] has found that febuxostat did not increase the risk of major adverse cardiovascular events (MACE) but may increase the risk of cardiovascular death. Herein, we conducted a systematic review and meta-analysis by including a higher number of RCTs than the previously published meta-analysis to examine the effects of febuxostat on mortality and MACE in patients with gout.

Methods {#sec1}
=======

This trial level meta-analysis was conducted in accordance with Cochrane collaboration guidelines[@bib12] and reported according to the Preferred Reporting Items for Systematic Review and Meta-Analysis protocols.[@bib13] The protocol of the present study was registered at PROSPERO register (CRD42019133121).

Study Search and Selection Criteria {#sec1.1}
-----------------------------------

The literature search was performed using electronic databases of PubMed/MEDLINE, Cochrane review, and EMBASE without language limitations through April 17, 2019, by two independent reviewers (H.E. and S.U.). The following keywords were used: febuxostat, hyperuricemia, gout, and clinical trial ([Supplementary Material](#appsec1){ref-type="sec"}, available online at <http://www.mcpiqojournal.org>). References of retrieved studies were screened for further relevant studies suitable for this meta-analysis.

The pre-determined inclusion criteria were: (1) RCTs comparing febuxostat vs control (placebo or allopurinol) among adult patients with hyperuricemia; and (2) studies reporting mortality and cardiovascular endpoints of interest. There were no restrictions on language, sample size, and follow-up durations. We excluded reviews, editorials, letters, and non-human studies. We also excluded observational studies as they carry risk of selection and attrition bias to minimize the risk of confounding.

Data Extraction and Quality Assessment {#sec1.2}
--------------------------------------

The data abstraction was performed on a pre-specified data collection form by two independent reviewers (A.B. and A.J.), and any discrepancy was resolved by a third reviewer (A.A.). The following information was abstracted: baseline characteristics of trials and participants, crude point estimates, raw events, sample sizes, and follow-up duration. Two reviewers (A.J. and A.B.) assessed the quality and certainty of the evidence under the supervision of third reviewer (A.A.) using the Jadad scale[@bib14] ([Supplemental Table 1](#appsec1){ref-type="sec"}, available online at <http://www.mcpiqojournal.org>), and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (GRADEpro GDT),[@bib15] which was classified as high, moderate, low, or very low ([Supplemental Tables 2](#appsec1){ref-type="sec"} and [3](#appsec1){ref-type="sec"}, available online at <http://www.mcpiqojournal.org>).[@bib16] The risk of bias assessment was determined using the Cochrane risk of bias scale ([Supplemental Figure 1](#appsec1){ref-type="sec"}, available online at <http://www.mcpiqojournal.org>). Publication bias was assessed using funnel plot ([Supplemental Figure 2](#appsec1){ref-type="sec"}, available online at <http://www.mcpiqojournal.org>), and Egger's regression test.

Outcomes of Interest {#sec1.3}
--------------------

The main outcomes of interest were cardiovascular mortality and all-cause mortality. The additional endpoints were MACE, myocardial infarction (MI), stroke, and new-onset hypertension. The definition of MACE in each of the involved trials is shown in [Supplemental Table 3](#appsec1){ref-type="sec"}.

Statistical Analysis {#sec1.4}
--------------------

Outcomes were pooled using a random effects Mantel-Haenszel model. The DerSimonian and Laird method was used for estimation of τ^2^. We reported effect sizes as risk difference (RD) with 95% CI. The 95% CIs that did not cross zero were considered statistically significant. We reported the number needed to treat or harm (NNT/H) for all outcomes. We used the *I*^*2*^ statistic to measure statistical heterogeneity; *I*^*2*^\>50% was considered to have significant heterogeneity. Sensitivity analyses were performed by limiting the results to patients with pre-existing cardiovascular disease (CVD), and by excluding one trial at a time. To assess whether the current meta-analysis was powered to assess 30% difference between groups with moderate heterogeneity, power analysis was performed as suggested by Borenstein et al.[@bib17] ([Supplemental Figure 3](#appsec1){ref-type="sec"}, available online at <http://www.mcpiqojournal.org>). This meta-analysis was 100% powered for primary endpoints.

Analyses were performed using Review Manager (RevMan) Version 5.3 (Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).

Results {#sec2}
=======

Of 661 articles, 67 full-text articles were reviewed after removal of duplicates. Finally, 15 RCTs encompassing 16,070 participants met the inclusion criteria ([Figure 1](#fig1){ref-type="fig"}).[@bib9]^,^[@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31] Egger's regression test did not detect significant publication bias (*P* (two-tailed) = .51).Figure 1Details of the search results.

Characteristics of Trials and Participants {#sec2.1}
------------------------------------------

[Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"} report baseline characteristics of trials and participants. The mean ± SD age was 58.1±11.7 years. The proportion of patients with hypertension varied from 27.7% to 100.0% and diabetes 6.9% to 100.0%. The median follow-up across the trials was 6.4 months (range: 4 to 24 months).Table 1Details of the Randomized Clinical TrialsStudy, yearNComparative treatmentStudy periodCountryFollow-up (mo)PopulationBecker et al, 2005[@bib25]760Febuxostat 80 mg vs febuxostat 120 mg vs allopurinolJuly 2002--February 2004United States and Canada12Gout and hyperuricemiaSchumacher et al, 2008[@bib23]1072Febuxostat 80 mg vs febuxostat 120 mg vs febuxostat 240 mg vs allopurinol vs placeboFebruary 2003--April 2004United States6.4GoutBecker et al, 2009[@bib18]1086Febuxostat 80 mg vs febuxostat 120 mg vs allopurinol---United States and Canada40GoutBecker et al, 2010[@bib24]2269Febuxostat 40 mg vs febuxostat 80 mg vs allopurinol---United States6GoutHuang et al, 2014[@bib20]516Febuxostat 40 mg vs febuxostat 80 mg vs allopurinolFebruary 2010--December 2010China6.4GoutNagakomi et al, 2015[@bib20]61Febuxostat 40 mg vs allopurinolSeptember 2011--April 2013Japan12Heart failure and hyperuricemiaSaag et al, 2016[@bib22]96Febuxostat 30 mg twice daily vs Febuxostat 40--80 mg once daily vs placebo--United States12Gout and chronic kidney diseaseDalbeth et al, 2017[@bib26]314Febuxostat 40--80 mg vs placebo--United States24GoutGunawardhana et al, 2017[@bib28]121Febuxostat 80 mg vs placebo--United States1.5Hypertension and hyperuricemiaGunawardhana et al, 2018[@bib27]189Febuxostat IR 40 mg vs febuxostat XR 40 mg vs febuxostat IR 80 mg vs febuxostat XR 80 mg vs placeboMay 2014--October 2015United States3GoutKimura et al, 2018[@bib30]443Febuxostat 10--40 mg vs placeboNovember 2012--January 2014Japan25Asymptomatic hyperuricemia and stage 3 chronic kidney diseaseMukri et al, 2018[@bib19]93Febuxostat 40 mg vs placebo---Malaysia6Diabetic nephropathy (chronic kidney disease stage 3 and 4) and hyperuricemiaWhite et al, 2018[@bib9]6190Febuxostat 40--80 mg vs allopurinolApril 2010--May 2017United States32Gout and previous cardiovascular eventsKojima et al, 2019[@bib31]1070Febuxostat 10--40 mg vs non-febuxostat group (allopurinol 100 mg given if serum uric acid was elevated)November 2013--October 2014Japan36Elderly patients aged ≥65 y with hyperuricemia (serum uric acid \>7.0 to ≤9.0 mg/dL) who had one or more risks for cerebral, cardiovascular, or renal diseaseSaag et al, 2019[@bib21]1790Febuxostat IR 40 mg vs febuxostat XR 40 mg vs febuxostat IR 80 mg vs febuxostat XR 80 mg vs placeboApril 2015--November 2016United States3GoutTable 2Baseline Characteristics of the Included Trials[a](#tbl2fna){ref-type="table-fn"}Study, yearTrial arm, dosage (mg)NMalesAge ± SD, yPatient population, nDMHTNCADBMIBecker et al, 2005[@bib25]FBX, 8025624351.8±11.7171062332.7±6.1FBX, 12025124352.0±12.1171132832.3±5.7ALP, 30025324351.6 ± 12.6191122332.6±6.1Schumacher et al, 2008[@bib23]FBX, 8026725151±12---1243833±6FBX, 12026925551±12---1243733±7FBX, 24013412654±13---702433±7ALP, 100-30026824952±12---1232733±6Placebo13412352±12---611832±6Becker et al, 2009[@bib18]FBX, 80649---51.4±11.95462957132.3±5.78FBX, 120292---50.9±11.57151153333.2±6.17ALP, 300145---51.0±11.3012731433.8±6.79Becker et al, 2010[@bib24]FBX, 4075772252.5±11.6889---42132.9±6.37FBX, 8075671053.0±11.79113---44032.9±6.39ALP, 200--30075670952.9±11.73110---43632.7±6.23Huang et al, 2014[@bib29]FBX, 4017216746.12±10.90---545725.63±2.80FBX, 8017216947.40±11.18---454725.25±2.64ALP, 30017216846.17±11.56---444525.44±2.53Nakagomi et al, 2015[@bib20]FBX, 40312269.3±109272023.6±2.4ALP, 100-300301871.8±812302423.1±3.1Saag et al, 2016[@bib22]FBX, 30 (twice daily)322567.3±11.111230---32.8±6.45FBX, 40--80 (once daily)322663.6±8.151531---34.2±7.30Placebo322666.3±12.051631---33.3±6.36Dalbeth et al, 2017[@bib26]FBX, 40--8015714550.1±11.7---------32.3±6.23Placebo15714351.4±12.4---------33.1±6.40Gunawardhana et al, 2017[@bib28]FBX, 80615052.2±10.5---43---31.99±5.13[^1]

Cardiovascular Mortality and All-Cause Mortality {#sec2.2}
------------------------------------------------

The use of febuxostat was not associated with a significant risk of cardiovascular mortality (RD, 0.12%; 95% CI, -0.25% to 0.49%; *P*=.53; *I*^*2*^=48%; NNH=454.5; low certainty evidence) ([Figure 2](#fig2){ref-type="fig"}*A*) or all-cause mortality (RD, 0.20%; 95% CI, -0.28% to 0.68; *P*=.42; *I*^*2*^ =60%; NNH=149.3; very low certainty of evidence) ([Figure 2](#fig2){ref-type="fig"}*B*).Figure 2(A) Forest plot of cardiovascular mortality. (B) Forest plot of all-cause mortality. M = Mantel; H = Haenszel.

Cardiovascular Outcomes {#sec2.3}
-----------------------

The use of febuxostat was not associated with a significant risk of MI (RD, -0.06%; 95% CI, -0.29% to 0.17%; *P*=.61; *I*^*2*^ =0%; NNH=128.2; moderate certainty evidence), MACE (RD, 0.40%; 95% CI, -0.34% to 1.13%; *P*=.29 *I*^*2*^ =26%; NNH=155.3; low certainty evidence), stroke (RD, 0.10%; 95% CI, -0.15% to 0.35%; *P*=.43; *I*^*2*^ =0%; NNH=476.2; moderate certainty evidence), or new onset hypertension (RD, 1.58%; 95% CI, -0.63% to 3.78%; *P*=.16; *I*^*2*^ =58%; NNH=44.8; very low certainty evidence) compared with control ([Supplemental Figures 4](#appsec1){ref-type="sec"} *A* to 4*D*, available online at <http://www.mcpiqojournal.org>).

Sensitivity Analyses {#sec2.4}
--------------------

In sensitivity analyses restricted to trials including only patients with pre-existing CVD (4 RCTs, 7442 participants), use of febuxostat was not associated with significant risk of cardiovascular mortality (RD, 0.48%; 95% CI, -0.58% to 1.54%; *P*=.37; *I*^*2*^ =30%; NNH=117.8; low certainty evidence), all-cause mortality (RD, 0.32%; 95% CI, -1.30% to 1.94%; *P*=.70; *I*^*2*^ =46%; NNH=94.8; low certainty evidence), MACE (RD 0.24% \[-1.01% to 1.49%\]; *P*=.71; I^2^ =0%; NNH=377.4; moderate certainty evidence), and MI (RD, -0.30%; 95% CI, -1.03% to 0.43%; *P*=.42; *I*^*2*^ =0%; NNH=396.8; moderate certainty evidence) ([Supplemental Figures 5](#appsec1){ref-type="sec"}*A* to *D*, available online at <http://www.mcpiqojournal.org>). Sensitivity analysis by excluding one trial at a time was not associated with significant changes in the results ([Supplemental Table 4](#appsec1){ref-type="sec"}, available online at <http://www.mcpiqojournal.org>).

Discussion {#sec3}
==========

In this systematic review and meta-analysis of 15 RCTs including more than 16,000 patients, we found that febuxostat was not associated with a significant risk of cardiovascular or all-cause mortality among patients with gout and hyperuricemia compared with control. In conformity, there was no significant risk of MACE, nonfatal MI, stroke, or new-onset hypertension with use of febuxostat vs control.

Observational studies have suggested a beneficial cardiovascular outcome with febuxostat in patients with gout.[@bib32]^,^[@bib33] This cardioprotective effect could be attributed to the lower frequent of gout flares which has a detrimental effect on the cardiovascular system.[@bib34] On the other hand, using data from an observational cohort study from Taiwan, Su et al[@bib35] found a significant increased risk of adverse cardiovascular events and mortality with febuxostat and the association was dose dependent. In 2018, White et al[@bib9] published the CARES trial, which was the largest reported RCT that evaluated the cardiovascular safety of febuxostat in patients with gout compared with allopurinol. This trial, which included 6190 patients, found no overall difference in MACE between the two groups, but there were more cardiovascular and all-cause mortality events in the febuxostat group. However, we did not find an association of febuxostat with cardiovascular or all-cause mortality in our analysis of pooled RCT data that included more than 16,000 patients. The CARES trial included patients with higher cardiovascular risk who had events rate more than 10% higher than the other trials, which could have contributed to this higher mortality rates seen in this trial.[@bib9] The mechanism behind any potential risks is unknown. Experimental trials have reported no cardiac toxic effect on both heart function and rhythm.[@bib36], [@bib37], [@bib38] Furthermore, the rates of MI, arrhythmias, and MACE were similar in both groups of the CARES trial and this was consistent with our analysis.

A recent meta-analysis[@bib11] had included 10 trials and found that febuxostat did not increase the risk of MACE but may increase the risk of cardiovascular death. We found that MACE was defined differently across different RCTs ([Supplemental Table 5](#appsec1){ref-type="sec"}, available online at <http://www.mcpiqojournal.org>) and using it as a primary outcome is unreliable. Therefore, we focused on cardiovascular mortality as the primary outcome. Our study has many other important strengths, including extensive search focusing on cardiovascular events, examining multiple individual MACE endpoints, a larger number of included trials, performance of a key sensitivity analysis, and analyzing the data using the RD instead of risk ratio because we are handling a dataset in which many of the event frequencies were zero; thus, using the risk ratio may exaggerate the effect of treatment.[@bib39]

Study Limitations {#sec3.1}
-----------------

On the other hand, our study also has some limitations worth mentioning. First, although we included a higher number of trials than the prior meta-analysis,[@bib11] there was high heterogeneity of study populations across the various trials. We tried to overcome that by pooling results using the random effects model and doing sensitivity analysis. Second, among these trials, the number of cardiovascular events were low in both febuxostat and control arms of the trials and this is likely because the primary endpoints of most of these studies were not cardiovascular events. Third, there were only limited number of studies which included only patients with history of CVD.[@bib9]^,^[@bib20]^,^[@bib28]^,^[@bib31] If future studies are planned, we recommend further trials that measure cardiovascular events and mortality as an outcome, defining MACE, and comparing the outcomes among different doses of febuxostat over a longer follow-up duration. Finally, there are many ongoing trials that are measuring cardiovascular events and mortality as an outcome such as the Febuxostat versus Allopurinol Streamlined Trial (FAST)[@bib40] trial (ISRCTN72443728) and other trials with specific types of patients; for example, the Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients (LUMINA) trial (NCT03200210) includes only patients on peritoneal dialysis, and the The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) trial (NCT03336203) includes patients with chronic kidney disease. All of these trials will help in estimating the associated risk of cardiovascular events and mortality with using febuxostat.

Conclusion {#sec4}
==========

This meta-analysis including 16,070 participants showed that there was no significant difference in cardiovascular mortality, all-cause mortality, MACE, MI, stroke, and new-onset hypertension between febuxostat and the control group.

Supplemental Online Material {#appsec1}
============================
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[^1]: ALP = allopurinol; BMI = body mass index; CAD = coronary artery disease; DM = diabetes mellitus; ER = extended release; FBX = febuxostat; HTN = hypertension; IR = immediate release.
